Tempus AI acquires Personalis for $1.5B to target the $20B MRD cancer monitoring market. Get full deal details and analysis.

Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.

Tempus is boosting its cancer offerings with a deal to buy out Personalis three years after the pair first teamed up in oncology. | Tempus is boosting its cancer offerings with a…